FY2025 · ended Dec 31, 2025 · Revenue $2.71B, +30.7% YoY · Filed Feb 18, 2026
Insulet Corporation (PODD) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.7 billion and net income of $247.1 million. Free cash flow was $377.7 million. As of Sep 30, 2026 it held $584.4 million in cash and investments and $44.2 million in total debt.
Revenue (TTM)
$3.19B
+26.5% vs year-ago TTM
Net income (TTM)
$428.70M
+74.1% vs year-ago TTM
Operating cash flow (TTM)
$509.00M
-4.6% vs year-ago TTM
Free cash flow (TTM)
$260.00M
-38.6% vs year-ago TTM
EPS (TTM)
$6.13
+81.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
70.40M
+0.2% vs prior year
Net cash
$540.20M
as of Sep 30, 2026
Operating margin
18.4%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PODD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Acton, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1145197
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.7B | $2.1B | $1.7B | $1.3B | $1.0B |
| Operating income | $473.8M | $308.9M | $220.1M | $37.6M | $126.0M |
| Net income | $247.1M | $418.3M | $206.3M | $4.6M | $16.8M |
| Diluted EPS | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 |
| Operating cash flow | $569.3M | $430.2M | $145.7M | $119.0M | -$68.1M |
| Free cash flow | $377.7M | $305.3M | $70.1M | -$3.9M | -$180.0M |
| Total assets | $3.2B | $3.1B | $2.6B | $2.3B | $2.0B |
| Total liabilities | $1.7B | $1.9B | $1.9B | $1.8B | $1.5B |
| Stockholders' equity | $1.5B | $1.2B | $732.7M | $476.4M | $556.3M |
| Cash and investments | $716.1M | $953.4M | $708.9M | $689.8M | $806.4M |
| Total debt | $70.3M | $168.0M | $105.3M | $1.4B | $1.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 10, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 1002 Insulet Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.